香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 科濟藥業控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統稱「本集 團」或「科濟藥業」）董事會（「董事會」）沉痛宣佈，本公司非執行董事郭炳森先生 （「郭先生」）於二零二五年九月二十四日安詳逝世。 郭先生為本集團服務逾十載，憑藉深厚的商業洞察與卓越的企業家視野，始終為 本集團發展提供核心支撐。在本集團戰略轉型、業務攻堅、風險應對等關鍵節 點，郭先生從未缺席，其精準決策與全力賦能，多次助力集團突破發展瓶頸，為 業務穩健推進奠定重要基礎。董事會代表本集團向郭先生的家人致以最深切的哀 悼，並對郭先生長年來為本集團的傾力奉獻與寶貴貢獻，致以最誠摯的謝意與崇 高的敬意。 承董事會命 科濟藥業控股有限公司 董事長 李宗海博士 香港，2025年9月24日 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份 ...

Core Viewpoint - The article discusses the promising advancements in "in vivo CAR-T" technology, which aims to make cancer treatment more accessible and affordable, potentially reducing costs to one-tenth of traditional methods and improving patient outcomes [3][4][5]. Group 1: Current Challenges in CAR-T Therapy - Traditional CAR-T therapy involves extracting a patient's T cells, modifying them in a lab, and reinfusing them, which is time-consuming (1-3 weeks) and costly (over 1 million yuan per treatment) [3][4]. - The complexity of the production process limits the widespread adoption of CAR-T technology, making it a "sky-high treatment" for ordinary people [3][4]. Group 2: Advancements in In Vivo CAR-T Technology - In vivo CAR-T technology allows for direct injection of carriers (like viruses or lipid nanoparticles) that modify T cells within the patient's body, eliminating the need for cell extraction [4]. - This method is expected to significantly reduce treatment costs and improve accessibility, with potential costs dropping to one-tenth of traditional CAR-T therapy [4][5]. - The treatment can show effects as quickly as three days after one or two intravenous injections, addressing the urgent needs of patients who cannot wait for traditional methods [4][5]. Group 3: Industry Implications - The shift towards in vivo CAR-T technology is attracting attention from both capital and industry, with multiple Chinese companies exploring this field [4]. - The maturation of in vivo CAR-T technology could lead to a future where patients receive effective cell therapy through simple injections, broadening the range of treatable diseases [5].

Group 1 - The company Zhaoli Pharmaceutical (300181.SZ) has a subsidiary, Zhaoli Innovation Medical, which holds shares in the Hong Kong innovative drug company Kexi Pharmaceutical-B (HK: 02171) [1] - Zhaoli Innovation Medical owns 28,385,012 shares of Kexi Pharmaceutical [1]

科济药业-B(02171)发布公告，于2025年9月18日，该公司根据首次公开发售后购股权计划的条款向348 名购股权承授人授出674.05万份购股权，惟须待购股权承授人接纳后方可作实。 董事会宣布，于2025年9月18日，公司根据首次公开发售后受限制股份单位计划的条款向196名受限制股 份单位承授人授出191.15万份受限制股份单位，惟须待受限制股份单位承授人接纳后方可作实。 授出受限制股份单位旨在通过拥有股份使合资格人士的利益与集团的利益一致，以鼓励及挽留彼等为集 团的长期增长及盈利作出贡献。 公司授出购股权旨在奖励雇员过往对公司取得成功的贡献，以鼓励彼等进一步为公司作出贡献，并使其 利益与公司及股东的整体最佳利益保持一致。 ...

智通财经APP讯，科济药业-B(02171)发布公告，于2025年9月18日，该公司根据首次公开发售后购股权 计划的条款向348名购股权承授人授出674.05万份购股权，惟须待购股权承授人接纳后方可作实。 公司授出购股权旨在奖励雇员过往对公司取得成功的贡献，以鼓励彼等进一步为公司作出贡献，并使其 利益与公司及股东的整体最佳利益保持一致。 董事会宣布，于2025年9月18日，公司根据首次公开发售后受限制股份单位计划的条款向196名受限制股 份单位承授人授出191.15万份受限制股份单位，惟须待受限制股份单位承授人接纳后方可作实。 授出受限制股份单位旨在通过拥有股份使合资格人士的利益与集团的利益一致，以鼓励及挽留彼等为集 团的长期增长及盈利作出贡献。 ...

Core Viewpoint - Company Kintor Pharmaceutical Co., Ltd. (02171.HK) announced the granting of stock options and restricted share units as part of its post-IPO incentive plans [1] Group 1: Stock Options - On September 18, 2025, the company granted a total of 6.7405 million stock options to 348 option grantees under the terms of its post-IPO stock option plan, pending acceptance by the grantees [1] Group 2: Restricted Share Units - On the same date, the company also granted 1.9115 million restricted share units to 196 grantees under the terms of its post-IPO restricted share unit plan, which is also subject to acceptance by the grantees [1]

CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (I) 根據首次公開發售後購股權計劃授出購股權；及 (II) 根據首次公開發售後受限制股份單位計劃授出受限制股份單位 (I) 根據首次公開發售後購股權計劃授出購股權 茲提述招股章程，內容有關於2021年11月30日採納的首次公開發售後購股權計劃 的主要條款。根據上市規則第17.06A條，董事會宣佈，於2025年9月18日，本公 司根據首次公開發售後購股權計劃的條款向348名購股權承授人授出6,740,500份 購股權，惟須待購股權承授人接納後方可作實。 授出購股權的詳情 向購股權承授人授出購股權之詳情如下： 授出購股權 每股股份20.99港元 的行使價： 購股權行使價每股股份20.99港元，相當於以下各項的較 高者：(i)聯交所 ...

Core Insights - Company Kogei Pharmaceuticals-B (02171.HK) announced the long-term follow-up results of its product Zevor-cel (CT053), a targeted BCMA autologous CAR-T cell therapy, which were presented at the 22nd International Myeloma Society (IMS) annual meeting [1] Group 1 - The updated results of the Phase I clinical trial for Zevor-cel were showcased in a poster presentation at the IMS annual meeting held on September 17, 2025, in Toronto [1]

Core Viewpoint - The long-term follow-up results of the CAR-T cell product Zevor-cel (CT053) for treating relapsed/refractory multiple myeloma were presented at the 22nd International Myeloma Society Annual Meeting [1] Group 1: Product Information - Zevor-cel is an autologous CAR-T cell product targeting BCMA, specifically designed for the treatment of multiple myeloma (MM) [1] - The product received approval from the National Medical Products Administration on February 23, 2024, for adult patients with relapsed or refractory multiple myeloma who have progressed after at least three lines of treatment [1] - Zevor-cel was granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designation by the FDA in 2019 [1] Group 2: Clinical Trial Updates - The updated results of the Phase I clinical trial were presented under the title "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" at the IMS annual meeting on September 17, 2025 [1]

赛恺泽® I期临床试验更新结果已于多伦多时间2025年9月17日早上，在第22 届IMS年会上进行壁报展 示，标题为"复发╱难治性多发性骨髓瘤患者接受 zevor-cel治疗的长期随访"("Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma")。 赛恺泽®是一种用于治疗多发性骨髓瘤(MM)的全人抗自体BCMA CAR-T细胞产品。国家药品监督管理 局于2024年2月23日批准赛恺泽®新药上市申请，用于治疗复发或难治性多发性骨髓瘤成人患者，既往 经过至少3线治疗后进展(至少使用过一种蛋白酶体抑制剂及免疫调节剂)。泽沃基奥仑赛注射液于2019 年获得美国 FDA的再生医学先进疗法(RMAT)及孤儿药称号。 科济药业-B(02171)发布公告，赛恺泽®(泽沃基奥仑赛注射液，产品编号： CT053，一种靶向BCMA的 自体CAR-T细胞产品)的长期随访更新结果已在第 22届国际骨髓瘤学会年会上进行壁报展示。 ...